Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 6.64% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Sep 2025, up 6.64%, and an annual FY2024 reading of $1.6 million, up 4.35% over the prior year.
  • Other Non-Current Liabilities was $1.8 million for Q3 2025 at Summit Therapeutics, roughly flat from $1.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.3 million in Q1 2024 and bottomed at $1.4 million in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $2.1 million, with a median of $1.8 million recorded in 2025.
  • The sharpest move saw Other Non-Current Liabilities crashed 48.52% in 2022, then skyrocketed 123.5% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $2.8 million in 2021, then plummeted by 48.52% to $1.4 million in 2022, then grew by 9.31% to $1.6 million in 2023, then increased by 4.35% to $1.6 million in 2024, then grew by 12.27% to $1.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SMMT at $1.8 million in Q3 2025, $1.8 million in Q2 2025, and $1.7 million in Q1 2025.